HIF1A and neoplasm: Our findings highlight the tumor-suppressive and glycolysis-inhibitory roles of HOXA9 in skin tissue, support our previous finding that miR-365 is an onco-miR for the progression of cSCC, and emphasize a newly identified miR-365-HOXA9-HIF-1α axis that may provide novel intervention targets for cSCC therapy.